- ICH GCP
- 미국 임상 시험 레지스트리
- 임상시험 NCT05923073
중등도에서 중증 활동성 크론병이 있는 소아 참가자를 대상으로 한 Guselkumab 연구 (MACARONI-23)
소아 크론병에서 효능 확립을 위한 IL-23 경로의 p19 억제에 대한 제3상, 다기관, 무작위, 플랫폼 연구
The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.
연구 개요
연구 유형
등록 (추정된)
단계
- 3단계
연락처 및 위치
연구 연락처
- 이름: Study Contact
- 전화번호: 844-434-4210
- 이메일: Participate-In-This-Study1@its.jnj.com
연구 장소
-
-
-
Rotterdam, 네덜란드, 3015 GD
- 모병
- Erasmus Medisch Centrum
-
-
-
-
-
Nordbyhagen, 노르웨이, 1474
- 모병
- Akershus Universitetssykehus HF
-
Oslo, 노르웨이, 424
- 모병
- Oslo University Hospital
-
Tromsø, 노르웨이, 9038
- 모병
- Universitetssykehuset Nord-Norge HF
-
Trondheim, 노르웨이, 7030
- 모병
- St. Olavs Hospital
-
-
-
-
-
Busan, 대한민국, 48108
- 모병
- Inje University Haeundae Paik Hospital
-
Daegu, 대한민국, 41404
- 모병
- Kyungpook National University Chilgok Hospital
-
Seoul, 대한민국, 03080
- 모병
- Seoul National University Hospital
-
Seoul, 대한민국, 06351
- 모병
- Samsung Medical Center
-
Seoul, 대한민국, 120-752
- 모병
- Severance Hospital Yonsei University Health System
-
-
-
-
California
-
Los Angeles, California, 미국, 90048
- 모병
- Cedars Sinai Medical Center
-
-
Connecticut
-
Hartford, Connecticut, 미국, 06106
- 모병
- Connecticut Children's Medical Center
-
-
Georgia
-
Atlanta, Georgia, 미국, 30322
- 모병
- Emory University
-
Atlanta, Georgia, 미국, 30342
- 모병
- Children's Center for Digestive Health Care
-
-
Indiana
-
Indianapolis, Indiana, 미국, 46202-5225
- 모병
- Riley Hospital for Children
-
-
Massachusetts
-
Boston, Massachusetts, 미국, 02115
- 모병
- Boston Childrens Hospital
-
-
New Jersey
-
Morristown, New Jersey, 미국, 07960
- 모병
- Goryeb Children's Hospital
-
-
New York
-
New York, New York, 미국, 10029
- 모병
- Icahn School of Medicine at Mount Sinai
-
New York, New York, 미국, 10032
- 모병
- Columbia University Medical Center
-
New York, New York, 미국, 10021-5663
- 모병
- Weill Cornell Medical College - Judith Jaffe Multiple Sclerosis Center
-
-
Ohio
-
Dayton, Ohio, 미국, 45404
- 모병
- The Children's Medical Center of Dayton
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, 미국, 19104
- 모병
- Children's Hospital of Philadelphia
-
-
Texas
-
Fort Worth, Texas, 미국, 76104
- 모병
- Cook Childrens Medical Center
-
-
Vermont
-
Colchester, Vermont, 미국, 05446
- 모병
- University of Vermont Medical Center
-
-
-
-
-
Brussels, 벨기에, 1090
- 모병
- Universitair Ziekenhuis Brussel
-
Brussels, 벨기에, 1200
- 모병
- Cliniques Universitaires Saint Luc
-
Ghent, 벨기에, 9000
- 모병
- Universitair Ziekenhuis Gent
-
Leuven, 벨기에, 3000
- 모병
- UZ Leuven
-
-
-
-
-
Campinas, 브라질, 13060-904
- 모병
- Sociedade Campineira de Educacao e Instrucao Hospital e Maternidade Celso Pierro
-
Curitiba, 브라질, 80250-060
- 모병
- Associacao Hospitalar de Protecao a Infancia Dr. Raul Carneiro
-
Goiânia, 브라질, 74605-020
- 모병
- Universidade Federal de Goias - Hospital das Clinicas da UFG
-
Porto Alegre, 브라질, 90035-074
- 모병
- Irmandade Santa Casa de Misericordia de Porto Alegre
-
Porto Alegre, 브라질, 90035-007
- 모병
- Hospital De Clinicas De Porto Alegre
-
Vitória, 브라질, 29040-091
- 모병
- Centro de Ciencias e Saude da Universidade Federal do Espirito Santo-Nucleo de Doencas Infecciosas
-
Votuporanga, 브라질, 100000
- 모병
- INTEGRAL Pesquisa e Ensino
-
-
-
-
-
Córdoba, 스페인, 14004
- 모병
- Hosp Reina Sofia
-
Sabadell, 스페인, 8208
- 모병
- Corporacio Sanitari Parc Tauli
-
Valencia, 스페인, 46026
- 모병
- Hosp. Univ. I Politecni La Fe
-
-
-
-
-
Glasgow, 영국, G51 4TF
- 모병
- Royal Hospital for Sick Children
-
London, 영국, WC1N 3JH
- 모병
- Great Ormond Street Hospital
-
Manchester, 영국, M13 9WL
- 모병
- Royal Manchester Children's Hospital
-
Manchester, 영국, M13 9WL
- 모병
- Nowgen Centre, Research and Innovation
-
Oxford, 영국, OX3 9DU
- 모병
- John Radcliffe Hospital
-
Sheffield, 영국, S10 2TH
- 모병
- Sheffield Children's Hospital
-
-
-
-
-
Vienna, 오스트리아, 1090
- 모병
- AKH - Medizinische Universitat Wien
-
-
-
-
-
Beersheba, 이스라엘, 84101
- 모병
- Soroka University Medical Center
-
Be’er Ya‘aqov, 이스라엘, 70300
- 모병
- Shamir Medical Center Assaf Harofeh
-
Jerusalem, 이스라엘, 9103102
- 모병
- Shaare Zedek Medical Center
-
Jerusalem, 이스라엘, 9124001
- 모병
- Hadassah Medical Center
-
Petah Tikva, 이스라엘, 4920235
- 모병
- Schneider Children's Medical Center
-
Rehovot, 이스라엘, 761001
- 모병
- Kaplan Medical Center
-
-
-
-
-
Alessandria, 이탈리아, 15121
- 모병
- A.O. Santi Antonio e Biagio e Cesare Arrigo
-
Bergamo, 이탈리아, 24127
- 모병
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII (Presidio Papa Giovanni XXIII)
-
Bologna, 이탈리아, 40124
- 모병
- Ospedale Bellaria, U.O.Cardiologia Az. USL di Bologna
-
Florence, 이탈리아, 50139
- 모병
- Azienda Ospedaliero Universitaria Ospedale Pediatrico Meyer
-
Milan, 이탈리아, 20154
- 모병
- Azienda Socio Sanitaria Territoriale Fatebenefratelli Presidio Ospedale dei Bambini Vittore Buzzi
-
Roma, 이탈리아, 161
- 모병
- AOU Policlinico Umberto I
-
-
-
-
-
Hirosaki, 일본, 036-8563
- 모병
- Hirosaki University Hospital
-
Kagoshima, 일본, 890-8544
- 모병
- Kagoshima University Hospital
-
Kashiwa-shi, 일본, 277-0871
- 모병
- Tsujinaka Hospital Kashiwanoha
-
Kobe, 일본, 650 0017
- 모병
- Kobe University Hospital
-
Saga, 일본, 849-8501
- 모병
- Saga University Hospital
-
Sendai, 일본, 989-3126
- 모병
- Miyagi Childrens Hospital
-
Setagaya Ku, 일본, 157 8535
- 모병
- National Center for Child Health and Development
-
Tokyo, 일본, 113-8431
- 모병
- Juntendo University Hospital
-
Tsu, 일본, 514 8507
- 모병
- Mie University Hospital
-
Ube, 일본, 755-8505
- 모병
- Yamaguchi University Hospital
-
Yokohama, 일본, 232-0024
- 모병
- Yokohama City University Medical Center
-
Yokohama, 일본, 230-8765
- 모병
- Saiseikai Yokohamashi Tobu Hospital
-
-
-
-
Nova Scotia
-
Halifax, Nova Scotia, 캐나다, B3K 6R8
- 모병
- Iwk Health Centre
-
-
Ontario
-
London, Ontario, 캐나다, N6A 5W9
- 모병
- London Health Sciences Centre Victoria Hospital
-
Toronto, Ontario, 캐나다, M5G 1X8
- 모병
- Hospital For Sick Children
-
-
-
-
-
Braga, 포르투갈, 4710-243
- 모병
- Hospital de Braga
-
Lisbon, 포르투갈, 1649-035
- 모병
- Centro Hospitalar de Lisboa Norte Hospital Santa Maria
-
Porto, 포르투갈, 4200-319
- 모병
- Centro Hospitalar de Sao Joao E.P.E.
-
-
-
-
-
Rzeszów, 폴란드, 35-302
- 모병
- Korczowski Bartosz Gabinet Lekarski
-
Warsaw, 폴란드, 04 501
- 모병
- WIP Warsaw IBD Point Profesor Kierkus
-
Warsaw, 폴란드, 04 730
- 모병
- Instytut Pomnik Centrum Zdrowia
-
-
-
-
-
Amiens, 프랑스, 80054
- 모병
- CHU Amiens-Hopital Nord
-
Lille, 프랑스, 59037
- 모병
- Hôpital Jeanne de FLANDRE, CHRU LILLE
-
Paris, 프랑스, 75019
- 모병
- Hôpital Robert Debré
-
Paris, 프랑스, 75015
- 모병
- Hôpital Necker - Enfants Malades
-
-
-
-
-
Nedlands, 호주, 6009
- 모병
- Perth Children's Hospital
-
South Brisbane, 호주, 4101
- 모병
- Mater Hospital Brisbane
-
Westmead, 호주, 2145
- 모병
- The Children's Hospital at Westmead
-
-
참여기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Participants must have a diagnosis of Crohn's Disease (CD) or fistulizing CD, with active colitis, ileitis, or ileocolitis, confirmed at any time in the past by clinical, endoscopic, and histologic criteria.
- Participants must have moderately to severely active CD (as defined by a baseline Pediatric Crohn's Disease Activity Index [PCDAI] score greater than or equal to [>=] 30)
- Participants must have endoscopy with evidence of active CD defined as Simple Endoscopic Score for Crohn's Disease (SES-CD) score greater than or equal to (>=) 6 (or >=4 for participants with isolated ileal disease) within 1 month of receiving study intervention at Week 0
- Participants must have a history of inadequate response, loss of response, or intolerance to immunomodulators (6-MP, AZA, or MTX), oral or IV corticosteroids, or biologic therapy/JAK inhibitor therapy; OR have a history of corticosteroid dependence; OR have a history of inadequate response to exclusive enteral nutrition (EEN)
Exclusion Criteria:
- Participants has complications of CD such as symptomatic strictures or stenosis, short gut syndrome, or any other manifestation that might be anticipated to require surgery.
- Participants must not have an abscess
- Participants must not have any kind of bowel resection within 26 weeks or any other intra-abdominal surgery within 12 weeks of baseline
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위
- 중재 모델: 병렬 할당
- 마스킹: 삼루타
무기와 개입
참가자 그룹 / 팔 |
개입 / 치료 |
|---|---|
|
실험적: Open-label induction phase: Guselkumab Intravenously (IV)
Participants will receive guselkumab dose IV based on their body weight during the 12-week open-label induction phase. |
Guselkumab will be administered subcutaneously.
다른 이름들:
Guselkumab will be administered intravenously.
다른 이름들:
|
|
실험적: Open-label induction phase: Guselkumab Subcutaneously (SC)
Participants will receive guselkumab dose SC based on their body weight during the 12-week open-label induction phase. |
Guselkumab will be administered subcutaneously.
다른 이름들:
Guselkumab will be administered intravenously.
다른 이름들:
|
|
실험적: Double-blind maintenance phase: Guselkumab SC Dose Regimen 1
At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 1 SC based on their body weight up to Week 48. |
Guselkumab will be administered subcutaneously.
다른 이름들:
Guselkumab will be administered intravenously.
다른 이름들:
|
|
실험적: Double-blind Maintenance Phase: Guselkumab SC Dose Regimen 2
At the end of the induction phase, Week 12 responders will be randomized into the double-blind maintenance phase to receive guselkumab dose regimen 2 SC based on their body weight up to Week 48. |
Guselkumab will be administered subcutaneously.
다른 이름들:
Guselkumab will be administered intravenously.
다른 이름들:
|
|
실험적: Open-label maintenance phase: Guselkumab SC
Week 12 non-responders will not be randomized and will enter an open-label maintenance phase to receive guselkumab SC dosing regimen based on their body weight up to Week 48. |
Guselkumab will be administered subcutaneously.
다른 이름들:
Guselkumab will be administered intravenously.
다른 이름들:
|
연구는 무엇을 측정합니까?
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of Participants with Clinical Remission at Week 52
기간: Week 52
|
Percentage of participants with clinical remission at Week 52 will be assessed. Clinical remission is defined as pediatric Crohn's Disease activity index (PCDAI) less than or equal to (<=) 10. |
Week 52
|
|
Percentage of Participants Who Achieve Endoscopic Response at Week 52
기간: Week 52
|
Percentage of participants who achieve endoscopic response at Week 52 will be assessed. Endoscopic response is defined as greater than or equal to (>=) 50 percent (%) reduction (global) and greater than (>) 50% reduction (U.S specific) from simplified endoscopic score-Crohn's Disease (SES-CD) score at baseline. |
Week 52
|
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Percentage of Participants with Clinical Response at Week 12
기간: Week 12
|
Percentage of participants with clinical response at Week 12 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30. |
Week 12
|
|
Percentage of Participants with Clinical Response at Week 52
기간: Week 52
|
Percentage of participants with clinical response at Week 52 will be assessed. Clinical responder is defined as a decrease from baseline in the PCDAI score of >=12.5 points with a total PCDAI score <30. |
Week 52
|
|
Percentage of Participants with Clinical Remission at Week 12
기간: Week 12
|
Percentage of participants with clinical remission at Week 12 will be assessed. Clinical remission is defined as PCDAI score <=10. |
Week 12
|
|
Percentage of Participants with Endoscopic Remission at Week 52
기간: Week 52
|
Percentage of participants with endoscopic remission at Week 52 will be assessed. Endoscopic remission is defined as SES-CD total score <=4 and at least a 2-point reduction from baseline and no subscore >1. |
Week 52
|
|
Percentage of Participants with Corticosteroid-free Remission at Week 52
기간: Week 52
|
Percentage of participants with corticosteroid-free remission at Week 52 will be assessed. Corticosteroid-free remission is defined as PCDAI score <=10 at Week 52 and not receiving corticosteroids for at least 90 days before Week 52. |
Week 52
|
|
Percentage of Participants with Sustained Clinical Remission at Weeks 12, 24, and 52
기간: Weeks 12, 24, and 52
|
Percentage of participants with sustained clinical remission at Weeks 12, 24, and 52 will be assessed. Sustained clinical remission is defined as PCDAI <=10 at Weeks 12, 24, and 52. |
Weeks 12, 24, and 52
|
|
Percentage of Participants with Clinical remission by Patient-Reported Outcome (PRO-2)
기간: Week 12 and/or Week 52
|
Percentage of participants with clinical remission by PRO-2 will be assessed. Clinical remission by PRO-2 is defined as stool frequency (SF) <=3 and abdominal pain (AP) <=1 and no worsening of SF and AP from baseline. |
Week 12 and/or Week 52
|
|
Serum Concentration of Guselkumab During Induction Phase
기간: From Week 0 to Week 12
|
Serum concentrations of guselkumab will be assessed. Serum samples will be analyzed to determine concentrations of guselkumab using a validated, specific, and sensitive immunoassay method. |
From Week 0 to Week 12
|
|
Trough Plasma Concentration (Ctrough) of Guselkumab During Maintenance Phase
기간: At Weeks 16, 24, 36, 48 and 52
|
Ctrough is defined as the serum concentration of guselkumab immediately prior (pre-dose) to the next drug administration. |
At Weeks 16, 24, 36, 48 and 52
|
|
Change from Baseline in Body Weight at Weeks 12, 24, and 52
기간: Baseline, Weeks 12, 24, and 52
|
Change from baseline in body weight at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Body Weight Percentiles at Weeks 12, 24, and 52
기간: Baseline, Weeks 12, 24, and 52
|
Change from baseline in body weight percentiles at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Body Weight z-scores at Weeks 12, 24, and 52
기간: Baseline, Weeks 12, 24, and 52
|
Change from baseline in body weight z-scores at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height at Weeks 12, 24, and 52
기간: Baseline, Weeks 12, 24, and 52
|
Change from baseline in height at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height Percentiles at Weeks 12, 24, and 52
기간: Baseline, Weeks 12, 24, and 52
|
Change from baseline in height percentiles at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height z-scores at Weeks 12, 24, and 52
기간: Baseline, Weeks 12, 24, and 52
|
Change from baseline in height z-scores at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Change from Baseline in Height Velocity at Weeks 12, 24, and 52
기간: Baseline, Weeks 12, 24, and 52
|
Change from baseline in height velocity at Weeks 12, 24, and 52 will be assessed. |
Baseline, Weeks 12, 24, and 52
|
|
Percentage of Participants with Clinical Remission
기간: Week 52
|
Percentage of participants with clinical remission who were assigned to guselkumab dose regimen 1 and did not receive rescue therapy at Week 52 will be assessed. Clinical remission is defined as PCDAI score <=10. |
Week 52
|
|
Percentage of Participants Who Achieve Endoscopic Response
기간: Week 52
|
Percentage of participants who achieve endoscopic response who were assigned to q4w maintenance therapy and did not receive rescue therapy at Week 52 will be assessed. Endoscopic response is defined as >=50% reduction (global) and >50% reduction (U.S specific) from SES-CD score at baseline. |
Week 52
|
|
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
기간: Up to Week 64
|
An AE is any untoward medical occurrence in a clinical study participant administered a pharmaceutical (investigational or non-investigational) product that does not necessarily have a causal relationship with the intervention. An SAE is is any untoward medical occurrence that at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product and is medically important. |
Up to Week 64
|
공동 작업자 및 조사자
수사관
- 연구 책임자: Clinical Trial, Janssen Research & Development, LLC
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
기본 완료 (추정된)
연구 완료 (추정된)
연구 등록 날짜
최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
키워드
기타 연구 ID 번호
- CR109212
- 2021-006282-37 (EudraCT 번호)
- CNTO1959PBCRD3007 (기타 식별자: Janssen Research & Development, LLC)
- 2023-504735-41-00 (레지스트리 식별자: EUCT number)
- 2023 (미국 NIH 보조금/계약)
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
IPD 계획 설명
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .